Low dose versus standard dose rituximab for the treatment of antiphospholipid syndrome: A pilot study from a tertiary medical center

BACKGROUND: To investigate the therapeutic effects and safety of low-dose and standard-dose rituximab (RTX) in the treatment of antiphospholipid syndrome (APS). METHODS: In this real-world study, we included 22 consecutive patients with APS who received RTX. Standard dose (SD) was defined as an over...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Yuzhou, Zhong, Xue, Zhao, Yawei, Li, Gongming, Ye, Hua, Li, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670802/
https://www.ncbi.nlm.nih.gov/pubmed/36405743
http://dx.doi.org/10.3389/fimmu.2022.971366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670802/
https://www.ncbi.nlm.nih.gov/pubmed/36405743
http://dx.doi.org/10.3389/fimmu.2022.971366

Ejemplares similares